Sep 11, 2025 07:00AM Lunai Bioworks subsidiary BioSymetrics and Brigham and Women’s Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025 08:47AM Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025 08:50AM Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025 10:06AM Lunai Bioworks retains defense consultant for bioweapon countermeasures

Sep 4, 2025 10:05AM Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025 09:45AM Renovaro changes name to Lunai Bioworks to reflect AI biodefense focus

Aug 27, 2025 09:45AM Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025 10:45AM Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 28, 2025 10:38AM Renovaro receives multiple US patent allowances for AI technology

Jul 28, 2025 10:38AM Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 17, 2025 09:15AM Renovaro publishes peer-reviewed study on dendritic cell therapy

Jul 17, 2025 09:15AM Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025 08:03AM Renovaro converts $9.7 million debt to equity through share issuance

Jul 9, 2025 08:00AM Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025 09:21AM Renovaro Biosciences (RENB) Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 30, 2025 09:21AM Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025 09:16AM Renovaro Biosciences (RENB) Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 14, 2025 09:15AM Renovaro Biosciences (RENB) Launches Augusta

May 13, 2025 09:16AM Renovaro Biosciences (RENB) and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 9, 2025 09:25AM Renovaro Biosciences (RENB) and BioSymetrics Close Merger

Apr 4, 2025 09:41AM Renovaro Biosciences (RENB) Provides Update to Definitive Agreement with Predictive Oncology (POAI)

Feb 26, 2025 01:25PM Renovaro Biosciences (RENB) and BioSymetrics Announce Definitive Merger Agreement

Feb 26, 2025 09:15AM Renovaro Biosciences (RENB) Announces $15M in Equity Committed

Jan 6, 2025 09:10AM Predictive Oncology (POAI) to be Acquired by Renovaro

Dec 30, 2024 09:01AM Renovaro Biosciences (RENB) Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 20, 2024 03:40PM Renovaro Biosciences (RENB) Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024 09:00AM Renovaro Biosciences (RENB) Enters into a Strategic Collaboration with Nebul

Nov 4, 2024 08:31AM Renovaro Biosciences (RENB) Issues Shareholder Letter

Oct 16, 2024 09:28AM Renovaro Biosciences (RENB) Announces Strategic Restructuring and Leadership Transition

Sep 19, 2024 09:01AM Renovaro Biosciences (RENB): PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

Sep 11, 2024 09:15AM Renovaro Biosciences (RENB): RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Jun 14, 2024 09:06AM Renovaro Biosciences (RENB) Announces $10M in Equity Committed